Q2 FY2026 · ended Jun 30, 2026 · Revenue $500,000 · Filed Aug 10, 2026
Palisade Bio, Inc. (PALI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $500,000 and a net loss of $10.6 million.
Revenue
$500,000
Net income
$-10.57M
-279.8% vs year-ago quarter
Operating cash flow
$-7.60M
-318.4% vs year-ago quarter
Free cash flow
$-2.38M
+24.0% vs prior quarter
EPS
$-0.05
+91.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
174.27M
+1811.0% vs year-ago quarter
Net cash
$133.38M
Q4 FY2025
Operating margin
-7069.8%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PALI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1357459
- Former names
- PALISADE BIO, INC. (until Oct 30, 2026); Seneca Biopharma, Inc. (until Apr 26, 2021); Neuralstem, Inc. (until Jan 23, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $500,000 | $0 | $0 | $0 | $0 |
| Operating income | -$11.7M | -$10.7M | -$10.0M | -$2.9M | -$2.8M |
| Net income | -$10.6M | -$9.6M | -$8.9M | -$2.9M | -$2.8M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.04 | -$0.38 | -$0.58 |
| Operating cash flow | -$7.6M | -$3.9M | -$3.1M | -$3.6M | -$1.8M |
| Total assets | $127.3M | $133.3M | $134.3M | $7.0M | $6.7M |
| Total liabilities | $5.6M | $6.0M | $5.0M | $3.8M | $4.0M |
| Stockholders' equity | $121.7M | $127.4M | $129.4M | $3.2M | $2.6M |
| Cash and investments | $125.2M | $132.6M | $133.4M | $5.2M | $5.4M |
| Total debt | — | — | $0 | $0 | $24,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
All 1000 Palisade Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.